# Tesetaxel as First-line Therapy for Metastatic Breast Cancer

> **NCT01221870** · PHASE2 · UNKNOWN · sponsor: **Genta Incorporated** · enrollment: 81 (estimated)

## Conditions studied

- Breast Neoplasm

## Interventions

- **DRUG:** Tesetaxel once every 3 weeks
- **DRUG:** Tesetaxel once weekly

## Key facts

- **NCT ID:** NCT01221870
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-11
- **Primary completion:** 2012-10
- **Final completion:** 2013-01
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2012-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01221870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01221870, "Tesetaxel as First-line Therapy for Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01221870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*